Toggle navigation
About
Abstract
Editorial Board
Publication Schedule
Subscription & Newsletter
Contact
Issue
13-3
Table of Contents
Editors Selection
Glaucoma Dialogue
Glaucoma Opinion
Abstracts
Abstracts
Abstracted Journals
Classification List
Index of Authors
Search
Home
Abstracts
Journals
Journal #1321
advertisement
Value in Health
13
Showing records 1 to 13 |
Display all abstracts in
Value in Health
46872
Quality of life in ocular hypertension and primary open angle glaucoma
Wolfram C; Lorenz K; Shlaen R; Verboven Y; Pfeiffer N
Value in Health
2010; 13: A402
46873
Safety profile of latanoprost versus timolol in patients with open angle glaucoma or ocular hypertension: Post 2000 setting
Gupta J; Siddiqui MK; Jindal R; Sehgal M
Value in Health
2011; 14: 54
46874
A discrete event simulation to optimise the allocation of constrained hospital resources for glaucoma
Crane GJ; Karnon J; Kymes S; Casson R; Metcalfe A; Hiller JE
Value in Health
2011; 14: A55
46878
Cost of glaucoma in the United Kingdom according to the UK GPRD
Salmon J; Lafuma A; Robert J; Berdeaux G
Value in Health
2010; 13: 398
46876
Cost-effectiveness analysis of travoprost followed by fixed combination travoprost/timolol treatment sequence (T-TTFC) compared to latanoprost followed by latanoprost/timolol fixed combination (L-LTFC) for patients with open angle glaucoma or ocular hyper
Taylor M; Tan R
Value in Health
2010; 13: 509
46871
Cost-effectiveness analysis of formulary management strategies for first-line agents used in open-angle glaucoma and ocular hypertension
Blaser DA; Ousterhout MM; Gagnon JM; Calabrese D
Value in Health
2011; 14: A55
46875
Burden of disease in patients with glaucoma in China: Results from 2009 national health and wellness survey
Tang B; Annunziata K; Zhong Z; Dong P; Xuan J
Value in Health
2010; 13: 562-563
46877
Costs and effects of fixed combination therapies in open angle glaucoma
Wickstrom J; Centofanti M; Johnson M
Value in Health
2010; 13: 399-400
46879
Costs of glaucoma in Sweden - A pilot study
Svensson J; Berdeaux G; Bergstrom A; Forsby M; Ghatnekar O
Value in Health
2010; 13: 399
46880
Development of a multiattribute instrument for estimating utilities (preference weights) in people with glaucoma from the national eye institute visual functioning questionnaire (NEI-VFQ)
Kymes S; Peters CM; Beusterien K; Kotak S; Grinspan J; Stwalley D; Pleil A
Value in Health
2011; 14: 56
46882
Glaucoma disease progression states: Establishing a direct, quantitative link between visual field defects and utility loss
Gerlier L; Lamotte M; Verboven Y
Value in Health
2010; 13: 248
46883
Predictive factors of glaucoma treatment cost in Germany
Lorenz K; Wolfram C; Claus V; Plesnila-Frank C; Verboven Y; Pfeiffer N
Value in Health
2010; 13: 398-399
46881
Cost-effectiveness of brinzolamide/timolol fixed combination (BTFC) versus dorzolamide/timolol fixed combination (DTFC) for patients with open angle glaucoma in Korea and Taiwan
Tan R
Value in Health
2010; 13: 563
Issue
13-3
Table of Contents
Editor's Selection
Change Issue
24-1 (2024)
23-4 (2023)
23-3 (2023)
23-2 (2023)
23-1 (2022)
22-4 (2022)
22-3 (2022)
22-2 (2021)
22-1 (2021)
21-4 (2021)
21-3 (2021)
21-2 (2021)
21-1 (2020)
20-4 (2020)
20-3 (2020)
20-2 (2019)
20-1 (2019)
19-4 (2019)
19-3 (2018)
19-2 (2018)
19-1 (2018)
18-4 (2017)
18-3 (2017)
18-2 (2017)
18-1 (2017)
17-4 (2016)
17-3 (2016)
17-2 (2016)
17-1 (2016)
16-4 (2015)
16-3 (2015)
16-2 (2015)
16-1 (2014)
15-4 (2014)
15-3 (2014)
15-2 (2013)
15-1 (2013)
14-4 (2013)
14-3 (2013)
14-2 (2013)
14-1 (2012)
13-4 (2012)
13-3 (2011)
13-2 (2011)
13-1 (2011)
12-4 (2011)
12-3 (2010)
12-2 (2010)
12-1 (2010)
11-4 (2010)
11-3 (2009)
11-2 (2009)
11-1 (2009)
10-4 (2009)
10-3 (2008)
10-2 (2008)
10-1 (2008)
9-4 (2008)
9-3 (2007)
9-2 (2007)
9-1 (2007)
8-4 (2007)
8-3 (2006)
8-2 (2006)
8-1 (2006)
7-3 (2006)
7-2 (2005)
7-1 (2005)
6-3 (2005)
6-2 (2004)
6-1 (2004)
5-3 (2004)
5-2 (2003)
5-1 (2003)
4-3 (2003)
4-2 (2002)
4-1 (2002)
3-3 (2002)
3-2 (2001)
3-1 (2001)
2-3 (2001)
2-2 (2000)
2-1 (2000)
1-3 (2000)
1-2 (1999)
1-1 (1999)
advertisement